Automating the Wet Lab for Protein Design
Adaptyv Bio, a biotechnology company based in Lausanne, Switzerland, has closed a Series A funding round. The startup raised a total of €34.35 million in this latest investment phase. This capital injection supports its mission to develop automated wet labs. These facilities are designed specifically for AI-driven protein engineering. The move positions the firm to accelerate its technological roadmap significantly.
Breaking news
Echo Software Acquires Minimus Assets to Strengthen AI‑Driven Container Security
Plaud One Redefines Headphones for AI Note‑Taking
Apple Event Logo Suggests iPhone 18 Pro May Feature New Colors and Camera Upgrade
Plaud unveils smart earbuds that capture audio and execute tasks automaticallyThe new funding allows Adaptyv to expand its infrastructure for agentic biology. The company focuses on creating systems where artificial intelligence agents can operate laboratory equipment autonomously. This approach aims to streamline the complex process of designing and testing proteins. By automating physical experiments, the startup seeks to reduce human error and increase throughput. The technology bridges the gap between digital simulation and real-world biological validation.
Protein engineering is traditionally a slow and labor-intensive field. Researchers often spend months running manual experiments to test new molecular structures. Adaptyv’s platform changes this dynamic by integrating robotics with advanced software. The system enables continuous, high-throughput experimentation without constant human oversight. This automation is critical for handling the vast number of variables in biological research. It allows scientists to iterate designs faster than ever before. The core value proposition lies in speed and precision. By removing bottlenecks in the experimental workflow, the company hopes to unlock new therapeutic possibilities. Investors see this as a key enabler for next-generation drug discovery.
Why Agentic Biology Matters for Future Research
Agentic biology refers to AI systems that not only analyze data but also execute actions. In this context, the AI agents plan experiments, run them, and interpret results independently. This level of autonomy is rare in traditional biotech settings. Most current tools require significant human intervention at every step. Adaptyv aims to change that paradigm entirely. The raised funds will likely go toward scaling their hardware and refining their algorithms. The company plans to hire additional engineers and scientists to support this growth. As the biotech industry faces pressure to reduce development costs, such innovations become essential. They offer a scalable solution to the stagnation in protein-based therapies.
The successful raise signals strong investor confidence in the Swiss biotech sector. It highlights the growing importance of automation in life sciences. For Adaptyv, the next steps involve deploying these automated labs in partner facilities. The long-term goal is to create a standardized platform for global researchers. If successful, this could dramatically shorten the timeline for bringing new treatments to market. The industry is watching closely to see if this model can scale effectively.
Frequently Asked Questions
How much did Adaptyv Bio raise in its Series A? The company secured €34.35 million in its recent Series A funding round. This capital is dedicated to building and scaling their automated laboratory infrastructure.
What is the primary focus of Adaptyv’s technology? The startup develops automated wet labs specifically for AI-driven protein engineering. Their system allows AI agents to conduct biological experiments with minimal human input.
Where is Adaptyv Bio headquartered? The biotechnology startup is based in Lausanne, Switzerland. This location places it within a major European hub for scientific innovation.
